- Home
- CB vs IDYA Comparison
CB vs IDYA Comparison
Compare CB & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CB | IDYA |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 122.4B | 2.9B |
| IPO Year | 1993 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CB | IDYA |
|---|---|---|
| Price | $312.89 | $35.13 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 13 |
| Target Price | ★ $309.65 | $49.18 |
| AVG Volume (30 Days) | ★ 2.0M | 981.7K |
| Earning Date | 01-27-2026 | 02-12-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 23.94 | N/A |
| Revenue | ★ $58,842,000,000.00 | $214,834,000.00 |
| Revenue This Year | N/A | $2,662.86 |
| Revenue Next Year | $5.28 | N/A |
| P/E Ratio | $13.09 | ★ N/A |
| Revenue Growth | 7.43 | ★ 5377.66 |
| 52 Week Low | $252.16 | $13.45 |
| 52 Week High | $314.40 | $37.08 |
Technical Indicators
Market Signals| Indicator | CB | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 68.65 | 56.05 |
| Support Level | $308.50 | $33.11 |
| Resistance Level | $313.46 | $34.45 |
| Average True Range (ATR) | 4.41 | 1.24 |
| MACD | 0.31 | -0.01 |
| Stochastic Oscillator | 93.01 | 47.11 |
Price Performance
Historical ComparisonAbout CB Chubb Limited
ACE acquired Chubb in the first quarter of 2016 and assumed the Chubb name. The combination made the new Chubb one of the largest domestic property and casualty insurers, with operations in 54 countries spanning commercial and personal P&C insurance, reinsurance, and life insurance.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.